Can‑Fite BioPharma Ltd. received a Notice of Allowance from Brazil’s National Institute of Industrial Property for its CF602 patent application, which covers the use of the drug as an oral or topical therapy for erectile dysfunction in diabetic patients and those who do not respond to existing PDE5 inhibitors.
The allowance extends the company’s intellectual‑property protection for CF602 beyond the United States and Europe, where the drug has already secured patents. CF602 is an allosteric modulator of the A3 adenosine receptor and has shown promising pre‑clinical results in diabetic rat models, including full erectile recovery after a single dose and improved endothelial function.
The global erectile‑dysfunction market is estimated at $3.2 billion, and a sizable segment—30‑35 % of patients—remains untreated because they are non‑responders or have contraindications to current therapies. By securing protection in Brazil, Can‑Fite positions CF602 to address this unmet need in a large emerging market.
CEO Motti Farbstein said the Brazilian allowance “geographically expands intellectual property protection for CF602 in ED beyond the major markets of the U.S. and Europe where patents have already been granted.” He added that the drug “has the potential to meet a large and unmet need” among diabetic men and non‑responders.
The allowance is a regulatory milestone, but it is not a final patent grant. Formal approval and commercialization timelines remain uncertain, and CF602 is still in the pre‑clinical stage. The company’s broader A3 adenosine‑receptor platform also underpins other candidates, such as Piclidenoson for psoriasis and Namodenoson for liver cancer.
Can‑Fite has faced financial challenges in recent quarters, reporting negative margins and declining revenue growth. The patent allowance does not immediately translate into revenue, but it strengthens the company’s competitive position and may support future licensing or commercialization agreements in Brazil.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.